4 May 2022
Physiomics plc
("Physiomics") or ("the Company")
Physiomics expands technical team
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Cristian Gradinaru has joined its technical team as a Senior PKPD Modeller.
Cristian holds a PhD from the Technical University of Copenhagen, Denmark in Stochastic Modelling of Biological Systems, and an MSc from Stanford University, USA in Biophysics. He has held senior scientific roles at companies including Circassia Pharmaceuticals and F-star Biotechnology where he led pre-clinical and clinical projects focused on PKPD modelling.
Dr Jim Millen, CEO, commented "We're delighted that Cristian has chosen to join the Physiomics team. He will provide additional expertise and capacity to support our expanding client base and we look forward to working with him".
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.